03:51 PM EST - Oncolytics Biotech Inc. : announced today that a U.S. Phase I study of REOLYSIN(®) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrolment. Oncolytics Biotech Inc.
shares T.ONC are trading down $0.05 at $6.21.
